FDA OKs new Covid vaccine, available soon
The CDC recommends the new booster to combat the widely-circulating KP.2 strain
What happened
The Food and Drug Administration approved updated Covid-19 vaccines from Pfizer and Moderna yesterday. The new boosters target the KP.2 strain and related offshoots of the Omicron variant that have been spreading in late summer. The Centers for Disease Control and Prevention recommends the new shot for everyone six months and older.
Who said what
Last year's vaccines, which inoculated against a strain no longer in circulation, "offered moderate protection against getting infected" and a "stronger guard against severe disease," The New York Times said. When the match between virus and vaccine "is very good, as we anticipate it would be with the current circulating strains, you get actual protection from infection for several months," said Dr. Paul Sax at Brigham and Women's Hospital in Boston.
What next?
The updated vaccines should be available in pharmacies and clinics within days, at no cost to most people with health insurance and uninsured children. But "unless you're very concerned about acquiring Covid right now, my recommendation would be to get it in September or October," Dr. William Schaffner at the Vanderbilt University School of Medicine said to The Wall Street Journal. "That will provide the best protection throughout the winter season."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
When will mortgage rates finally start coming down?
The Explainer Much to potential homebuyers' chagrin, mortgage rates are still elevated
By Becca Stanek, The Week US Published
-
Women are getting their own baseball league again
In the Spotlight The league is on track to debut in 2026
By Justin Klawans, The Week US Published
-
Giant TVs are becoming the next big retail commodity
Under the Radar Some manufacturers are introducing TVs over 8 feet long
By Justin Klawans, The Week US Published
-
ACA opens 2025 enrollment, enters 2024 race
Speed Read Mike Johnson promises big changes to the Affordable Care Act if Trump wins the election
By Peter Weber, The Week US Published
-
The dark side of the contraceptive coil
Under the Radar Study linking hormonal IUD to increased breast cancer risk adds to growing concerns about whether the benefits of the coil outweigh the risks
By Harriet Marsden, The Week UK Published
-
Pink cocaine: the new drug cocktail responsible for an increasing number of deaths
In the Spotlight The substance has been linked to the death of Liam Payne and named in a lawsuit against Sean 'Diddy' Combs
By Justin Klawans, The Week US Published
-
McDonald's sued over E. coli linked to burger
Speed Read The outbreak has sickened at least 49 people in 10 states and left one dead
By Rafi Schwartz, The Week US Published
-
Why scurvy is on the rise
The Explainer Cost of living and poor dietary choices fuelling a potential resurgence of condition associated with the Age of Sail
By Richard Windsor, The Week UK Published
-
What went wrong at CVS?
Today's Big Question Pharmacy chains are in crisis
By Joel Mathis, The Week US Published
-
Long Covid: study shows damage to brain's 'control centre'
The Explainer Research could help scientists understand long-term effects of Covid-19 as well as conditions such as MS and dementia
By The Week UK Published
-
The 'game-changing' treatment for schizophrenia
The Explainer US poised to approve KarXT as new antipsychotic treatment for disorder, which could offer reduced side-effects
By Harriet Marsden, The Week UK Published